Fermion Oy Fermion Oy

X
[{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Domainex"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,475.0 million","upfrontCash":"$75.0 million","newsHeadline":"Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Precision BioSciences"},{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Discovery Life Sciences Acquires ReachBio Research Labs","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Reachbio Research Labs"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The Acquisition aims to enhance cell biology capabilities and accelerate assessments of potential new drug targets in hematologic diseases, cell and gene therapy, immunology, oncology, and immuno-oncology.

            Lead Product(s): Undisclosed

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Discovery Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the Agreement, Precision will develop an ARCUS nuclease and conduct in vitro characterization, with Novartis then assuming responsibility for all subsequent research, development, manufacturing and commercialization activities of PBGENE-HbE.

            Lead Product(s): PBGENE-HbE

            Therapeutic Area: Hematology Product Name: PBGENE-HbE

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $1,475.0 million Upfront Cash: $75.0 million

            Deal Type: Collaboration June 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership aims at discovering a drug that inhibits the protease target, activated Factor XII.

            Lead Product(s): Undisclosed

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: LUNAC Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY